{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:42:16Z","timestamp":1781196136513,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.intimp.2025.115297","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T14:24:37Z","timestamp":1754403877000},"page":"115297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Blockade of Bruton's tyrosine kinase suppresses B cell activation and antibody secretion in systemic lupus erythematosus"],"prefix":"10.1016","volume":"163","author":[{"given":"Xiaoyi","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenfang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Guo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.115297_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112077","article-title":"Roles of IRF4 in various immune cells in systemic lupus erythematosus","volume":"133","author":"Xiao","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.intimp.2025.115297_bb0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41584-020-0480-7","article-title":"New insights into the role of antinuclear antibodies in systemic lupus erythematosus","volume":"16","author":"Pisetsky","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2025.115297_bb0015","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-101921-042422","article-title":"Systemic lupus erythematosus pathogenesis: interferon and beyond","volume":"41","author":"Caielli","year":"2023","journal-title":"Annu. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115297_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102743","article-title":"An updated advance of autoantibodies in autoimmune diseases","volume":"20","author":"Xiao","year":"2021","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2025.115297_bb0025","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.berh.2018.09.004","article-title":"Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus","volume":"32","author":"Gergianaki","year":"2018","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115297_bb0030","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013010026","article-title":"The pathogenesis of lupus nephritis","volume":"24","author":"Lech","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.intimp.2025.115297_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102871","article-title":"Lupus nephritis: new progress in diagnosis and treatment","volume":"132","author":"Yu","year":"2022","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2025.115297_bb0040","article-title":"Advances in the management of systemic lupus erythematosus","volume":"383","author":"Morand","year":"2023","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.intimp.2025.115297_bb0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/BOR.0000000000000865","article-title":"B cells in systemic lupus erythematosus","volume":"34","author":"Szelinski","year":"2022","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.intimp.2025.115297_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102873","article-title":"B cell-targeted therapies in systemic lupus erythematosus","volume":"132","author":"Arbitman","year":"2022","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2025.115297_bb0055","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fimmu.2017.00068","article-title":"Human gingiva-derived mesenchymal stem cells inhibit Xeno-graft-versus-host disease via CD39-CD73-adenosine and IDO signals","volume":"8","author":"Huang","year":"2017","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115297_bb0060","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.4049\/jimmunol.1501740","article-title":"TGF-\u03b2-induced regulatory T cells directly suppress B cell responses through a noncytotoxic mechanism","volume":"196","author":"Xu","year":"2016","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115297_bb0065","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of Belimumab after rituximab in systemic lupus erythematosus : a randomized controlled trial","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann. Intern. Med."},{"issue":"9767","key":"10.1016\/j.intimp.2025.115297_bb0070","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2025.115297_bb0075","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.healun.2023.12.001","article-title":"Blockade of BLyS inhibits B-cell responses and antibody production for the prevention of chronic transplant rejection","volume":"43","author":"Liao","year":"2024","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.intimp.2025.115297_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.668131","article-title":"Targeting Bruton's tyrosine kinase in inflammatory and autoimmune pathologies","volume":"9","author":"Neys","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115297_bb0085","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/imm.13416","article-title":"The role of Bruton's tyrosine kinase in the immune system and disease","volume":"164","author":"McDonald","year":"2021","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2025.115297_bb0090","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fimmu.2019.00095","article-title":"Toll-like receptor signaling drives Btk-mediated autoimmune disease","volume":"10","author":"Rip","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115297_bb0095","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4049\/jimmunol.1302570","article-title":"Modeling the clinical phenotype of BTK inhibition in the mature murine immune system","volume":"193","author":"Benson","year":"2014","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115297_bb0100","doi-asserted-by":"crossref","first-page":"R243","DOI":"10.1186\/ar4086","article-title":"Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus","volume":"14","author":"Hutcheson","year":"2012","journal-title":"Arthritis Res. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2025.115297_bb0105","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/art.38047","article-title":"Suppression of glomerulonephritis in lupus-prone NZB \u00d7 NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase","volume":"65","author":"Mina-Osorio","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.intimp.2025.115297_bb0110","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.4049\/jimmunol.1301553","article-title":"Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis","volume":"191","author":"Rankin","year":"2013","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115297_bb0115","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90111","article-title":"Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN\u03b1-driven lupus nephritis","volume":"2","author":"Katewa","year":"2017","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.intimp.2025.115297_bb0120","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-017-1402-1","article-title":"HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus","volume":"19","author":"Kim","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2025.115297_bb0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.clim.2018.10.008","article-title":"BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis","volume":"197","author":"Chalmers","year":"2018","journal-title":"Clin. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2025.115297_bb0130","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.4049\/jimmunol.1800583","article-title":"Efficacy and Pharmacodynamic modeling of the BTK inhibitor Evobrutinib in autoimmune disease models","volume":"202","author":"Haselmayer","year":"2019","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115297_bb0135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-014-0178-8","article-title":"Ibrutinib: first global approval","volume":"74","author":"Cameron","year":"2014","journal-title":"Drugs"},{"issue":"25","key":"10.1016\/j.intimp.2025.115297_bb0140","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.intimp.2025.115297_bb0145","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.3390\/cells12162093","article-title":"Activated lymphocyte-derived DNA drives glucose metabolic adaptation for inducing macrophage inflammatory response in systemic lupus erythematosus","volume":"12","author":"Zhao","year":"2023","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.intimp.2025.115297_bb0150","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.cden.2013.06.003","article-title":"Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management","volume":"57","author":"Fortuna","year":"2013","journal-title":"Dent. Clin. N. Am."},{"issue":"1","key":"10.1016\/j.intimp.2025.115297_bb0155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2567.2012.03564.x","article-title":"B-cell receptor: from resting state to activate","volume":"136","author":"Treanor","year":"2012","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.intimp.2025.115297_bb0160","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115297_bb0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1615\/CritRevImmunol.2018025184","article-title":"The role of Bruton's tyrosine kinase in immune cell signaling and systemic autoimmunity","volume":"38","author":"Rip","year":"2018","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115297_bb0170","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3389\/fimmu.2017.01454","article-title":"Bruton's tyrosine kinase: an emerging key player in innate immunity","volume":"8","author":"Weber","year":"2017","journal-title":"Front. Immunol."},{"issue":"22","key":"10.1016\/j.intimp.2025.115297_bb0175","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1002\/j.1460-2075.1996.tb01014.x","article-title":"Distinct specificity in the recognition of phosphoinositides by the pleckstrin homology domains of dynamin and Bruton's tyrosine kinase","volume":"15","author":"Salim","year":"1996","journal-title":"EMBO J."},{"issue":"10","key":"10.1016\/j.intimp.2025.115297_bb0180","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1084\/jem.191.10.1745","article-title":"Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement","volume":"191","author":"Petro","year":"2000","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115297_bb0185","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1084\/jem.184.1.31","article-title":"A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2","volume":"184","author":"Takata","year":"1996","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115297_bb0190","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","article-title":"Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2025.115297_bb0195","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40164-022-00315-9","article-title":"Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect","volume":"11","author":"Wang","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2025.115297_bb0200","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/art.41811","article-title":"Efficacy, safety, and Pharmacodynamic effects of the Bruton's tyrosine kinase inhibitor Fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, Placebo-Controlled Trial","volume":"73","author":"Isenberg","year":"2021","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.intimp.2025.115297_bb0205","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/acr2.11511","article-title":"Efficacy and safety of the Bruton's tyrosine kinase inhibitor Evobrutinib in systemic lupus erythematosus: results of a phase II, randomized, double-blind, Placebo-Controlled Dose-Ranging Trial","volume":"5","author":"Wallace","year":"2023","journal-title":"ACR Open Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115297_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jnnp-2022-328799","article-title":"Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis","volume":"94","author":"Montalban","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925012883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925012883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T05:17:25Z","timestamp":1757913445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925012883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":42,"alternative-id":["S1567576925012883"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115297","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blockade of Bruton's tyrosine kinase suppresses B cell activation and antibody secretion in systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115297","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115297"}}